Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, Kwang-Pil | - |
dc.contributor.author | Ma, Seung Hyun | - |
dc.contributor.author | Yang, Jae-Jeong | - |
dc.contributor.author | Hwang, Yunji | - |
dc.contributor.author | Ahn, Choonghyun | - |
dc.contributor.author | Cho, Young-Min | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Park, Byung-Joo | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Park, Sue K. | - |
dc.date.available | 2020-02-28T08:42:27Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10190 | - |
dc.description.abstract | Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications. This randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy of metformin for controlling physical and metabolic profiles related to prognosis and adverse events in non-diabetic breast cancer patients. Female breast cancer patients (N = 105), at least 6 months post-mastectomy, with obesity (a parts per thousand yen25 kg/m(2)) and/or pre-diabetes (fasting blood sugar levels a parts per thousand yen100 mg/dL), were randomly assigned to three groups (placebo, metformin 500 mg, and metformin 1000 mg) stratified by tamoxifen use. A linear mixed model for repeated measurements among three groups and ANOVA for profile differences during 6 months of treatment were used for the intention-to-treat analysis. The metformin 1000 mg group had a significantly greater decline in glucose and HbA1c levels between treatment weeks 0 and 6 month (p = 0.008 and 0.009, respectively), and the declines increased with an increase in body mass index (BMI) level (p interaction with BMI = 0.007 and 0.067, respectively). A marginally significant different effect from the metformin 1000 mg treatment was detected for glucose and HbA1c levels (p interaction = 0.084 and 0.063, respectively) in the intention-to-treat analysis. Metformin 1000 mg treatment had a favorable effect on controlling glucose and HbA1C levels in obese non-diabetic breast cancer patients, indicating prognostic importance. Further trials are needed to elucidate the risk-benefit ratio of long-term use of metformin. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.subject | LIFE-STYLE INTERVENTION | - |
dc.subject | THERAPEUTIC OPPORTUNITY | - |
dc.subject | INSULIN | - |
dc.subject | MORTALITY | - |
dc.subject | WOMEN | - |
dc.title | Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000360669400013 | - |
dc.identifier.doi | 10.1007/s10549-015-3519-8 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, v.153, no.2, pp.361 - 370 | - |
dc.identifier.scopusid | 2-s2.0-84940960836 | - |
dc.citation.endPage | 370 | - |
dc.citation.startPage | 361 | - |
dc.citation.title | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 153 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Ko, Kwang-Pil | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Metformin | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Glucose | - |
dc.subject.keywordAuthor | Postoperative adjuvant | - |
dc.subject.keywordPlus | LIFE-STYLE INTERVENTION | - |
dc.subject.keywordPlus | THERAPEUTIC OPPORTUNITY | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | WOMEN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.